🇺🇸 FDA
Patent

US 11242339

Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria

granted A61KA61K31/517A61P

Quick answer

US patent 11242339 (Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria) held by United States Government as represented by the Department of Veterans Affairs expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United States Government as represented by the Department of Veterans Affairs
Grant date
Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/517, A61P, A61P21/00, A61P25/16